Drug Trial Radar · NCT01776424
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
Last checked: Nov 19, 2026Latest source record: Nov 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27,395
Actual
Start
Feb 28, 2013
Primary completion
Jul 21, 2017
Study completion Jun 15, 2021
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- Collaborators
- Population Health Research Institute; Janssen Research & Development, LLC
- First posted
- Jan 28, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are: * To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with coronary artery disease (CAD) or peripheral artery disease (PAD); * To determine whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects with CAD or PAD.
Conditions
- Prevention & Control
Interventions
Rivaroxaban (Xarelto, BAY59-7939)Drug
Tablet, 2.5 mg, twice daily, oral
Rivaroxaban (Xarelto, BAY59-7939)Drug
Tablet, 5 mg, twice daily, oral
AspirinDrug
Tablet, 100 mg, once daily, oral
Aspirin placeboDrug
Aspirin matching placebo, once daily, oral
Rivaroxaban placeboDrug
Rivaroxaban matching placebo, twice daily, oral
PantoprazoleDrug
Tablet, 40 mg, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole
Pantoprazole placeboDrug
Pantoprazole matching placebo, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) DeathTime frame: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
- The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) CriteriaTime frame: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
Locations
565 sites in 33 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mobile, Alabama
Site not named
Anaheim, California
Site not named
Laguna Hills, California
Site not named
Northridge, California
Site not named
Palo Alto, California
Site not named
Santa Rosa, California
Site not named
Sylmar, California
Site not named
Torrance, California
Site not named
Norwalk, Connecticut
Site not named
Stamford, Connecticut
Site not named
Trumbull, Connecticut
Site not named
Atlantis, Florida
Site not named
Clearwater, Florida
Site not named
Coral Springs, Florida
Site not named
Jacksonville Beach, Florida
Site not named
Largo, Florida
Site not named
New Port Richey, Florida
Site not named
Safety Harbor, Florida
Site not named
Sarasota, Florida
Site not named
Meridian, Idaho
Site not named
Arlington Heights, Illinois
Site not named
Hazel Crest, Illinois
Site not named
Davenport, Iowa
Site not named
West Des Moines, Iowa
Site not named
Crestview Hills, Kentucky
Site not named
Baltimore, Maryland
Site not named
Haverhill, Massachusetts
Site not named
Alpena, Michigan
Site not named
Jackson, Michigan
Site not named
St Louis, Missouri
Site not named
Kalispell, Montana
Site not named
New Brunswick, New Jersey
Site not named
Cortlandt Manor, New York
Site not named
Kingston, New York
Site not named
Saratoga Springs, New York
Site not named
Durham, North Carolina
Site not named
Pinehurst, North Carolina
Site not named
Elyria, Ohio
Site not named
Sandusky, Ohio
Showing 40 of 565 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.